13F-HR filed by Sands Capital Alternatives, LLC
Sands Capital Alternatives, LLC filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-13, with 20 holding rows worth $456,415,766.
- Accession
- 0001846444-25-000022
- Filer
- CIK 1846444
- Filed
- 2025-11-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 20 entries on the cover page, a total value of $456,415,766 stated on the cover page (in dollars after the unit check, H1), rows summing to $456,415,766 with VALUE read as dollars as filed, 13F file number 028-21032. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NU HLDGS LTD | G6683N103 | ORD SHS CL A | 7,175,434 | $114,878,698 | dollars as filed | |
| KLAVIYO INC COM SER A | 49845K101 | Stock | 3,515,065 | $97,332,150 | dollars as filed | |
| BETA BIONICS INC | 08659B102 | COMMON STOCK | 3,570,113 | $70,938,145 | dollars as filed | |
| COUPANG INC | 22266T109 | CL A | 795,006 | $25,599,193 | dollars as filed | |
| DOORDASH INC CL A | 25809K105 | Stock | 90,142 | $24,517,723 | dollars as filed | |
| SAMSARA INC COM CL A | 79589L106 | Stock | 598,914 | $22,309,547 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 10,950,000 | $17,739,000 | dollars as filed | |
| DATADOGINCCLASSA | 23804L103 | STOK | 118,707 | $16,903,877 | dollars as filed | |
| MONDAY COM LTD SHS | M7S64H106 | Stock | 58,336 | $11,299,100 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 170,000 | $10,103,100 | dollars as filed | |
| CROWDSTRIKE HLDGS INC | 22788C105 | COM | 15,615 | $7,657,284 | dollars as filed | |
| SNOWFLAKE INC COM SHS | 833445109 | Stock | 27,005 | $6,090,978 | dollars as filed | |
| ACUMEN PHARMACEUTICALS INC | 00509G209 | CMN | 3,417,075 | $5,843,198 | dollars as filed | |
| TOASTINCCLASSCLASSA | 888787108 | STOK | 156,604 | $5,717,612 | dollars as filed | |
| 10X GENOMICS INC CL A COM | 88025U109 | Stock | 481,770 | $5,631,891 | dollars as filed | |
| BIOAGE LABS INC COM | 09077V100 | Stock | 786,353 | $4,623,756 | dollars as filed | |
| ACRIVON THERAPEUTICS INC | 004890109 | CMN | 2,122,605 | $3,841,915 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 724,873 | $2,370,335 | dollars as filed | |
| CANDEL THERAPEUTICS INC | 137404109 | COMMON STOCK | 405,837 | $2,069,769 | dollars as filed | |
| FIGMA INC CL A | 316841105 | COM | 18,286 | $948,495 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001846444-25-000022 | this filing | 2025-11-13 | acceptance time not in the bulk data set |